The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Crystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Self-citationAcetylation: a regulatory modification to rival phosphorylation?
Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1176 · Cited by 1,160
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Self-citationKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Self-citation(2002) · PubMed · Cited by 732
Binary switches and modification cassettes in histone biology and beyond
Fischle, W., Wang, Y., & David Allis, C. (2003) · Nature · doi:10.1038/nature02017 · Cited by 629
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Self-citationHistone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Self-citationGui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Self-citationMitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 531
Self-citationHistone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Self-citationUngerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Self-citationHistone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Histone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
He, L.-Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M., & Pandolfi, P. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11537 · Cited by 303
Self-citationThe diversity of acetylated proteins.
Polevoda, B. V., & Sherman, F. (2002) · Genome biology · doi:10.1186/gb-2002-3-5-reviews0006 · Cited by 254
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Peart, M. J., Tainton, K. M., Ruefli, A. A., Dear, A. E., Sedelies, K. A., O’Reilly, L. A., Waterhouse, N. J., Trapani, J. A., & Johnstone, R. W. (2003) · PubMed · Cited by 233
Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA
Glaser, K. B., Li, J., Staver, M. J., Wei, R.-Q., Albert, D. H., & Davidsen, S. K. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.043 · Cited by 218
Piekarz, R. L., Robey, R. W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A. H., Torrico, S., & Bates, S. E. (2004) · Blood · doi:10.1182/blood-2003-09-3068 · Cited by 186
A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Piekarz, R., & Bates, S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383980 · Cited by 174
Chang, S. M., Kuhn, J. G., Rizzo, J., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2188 · Cited by 166
Murata, T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1071 · Cited by 163
Reid, T., Valone, F., Lipera, W., Irwin, D., Paroly, W., Natale, R., Sreedharan, S., Keer, H., Lum, B., Scappaticci, F., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.002 · Cited by 159
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, O. A., Tompkins, A. C., Weinberger, M., Headlee, D. J., Mccall, N., & Samid, D. (1994) · PubMed · Cited by 158
Tumor cell‐specific cytotoxicity by targeting cell cycle checkpoints
Warrener, R., Beamish, H., Burgess, A., Waterhouse, N. J., Giles, N., Fairlie, D. P., & Gabrielli, B. G. (2003) · The FASEB Journal · doi:10.1096/fj.02-1003fje · Cited by 149
Spotswood, H. T., & Turner, B. M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16547 · Cited by 146
Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 136
Rahmani, M., Yu, C., Dai, Y., Reese, E., Ahmed, W. B., Dent, P., & Grant, S. (2003) · PubMed · Cited by 132
Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
Qiu, L., Kelso, M. J., Hansen, C. P., West, M. L., Fairlie, D. P., & Parsons, P. G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690493 · Cited by 115
Deviant nucleosomes: the functional specialization of chromatin
Wolffe, A. P., & Pruss, D. (1996) · Trends in Genetics · doi:10.1016/0168-9525(96)81401-6 · Cited by 93
Gray, S. G., Qian, C., Furge, K., Guo, X., & Teh, B. T. (2004) · International Journal of Oncology · doi:10.3892/ijo.24.4.773 · Cited by 90
The Discovery of NVP-LAQ824: From Concept to Clinic
Remiszewski, S. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456675 · Cited by 88
Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Arts, J. J. G., Schepper, S. D., & Emelen, K. V. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456657 · Cited by 83
Kyrylenko, S., Kyrylenko, O., Suuronen, T., & Salminen, A. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3090-z · Cited by 74
Chang, S. M., Kuhn, J. G., Robins, H. I., Schold, S. C., Spence, A. M., Berger, M. S., Mehta, M. P., Bozik, M. E., Pollack, I., Schiff, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.984 · Cited by 61
A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer
Atmaca, A., Maurer, A. B., Heinzel, T., Göttlicher, M., Neumann, A., Al-Batran, S. E., Martin, E., Bartsch, I., Knuth, A. K., & Jaeger, E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3169 · Cited by 11
Histone Deacetylase Inhibitors: Novel Targeted Anti-Cancer Agents
Marks, P. A., & Kelly, W. K. (2005) · Springer eBooks · doi:10.1007/1-4020-3642-6_12 · Cited by 3
Self-citation
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Self-citationMarks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Self-citationThe role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 997
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801
Metadata
- Authors
- Kelly, W. K., & Marks, P. A.
- Venue
- Nature Clinical Practice Oncology
- Published
- 2005-03
- Volume
- 2
- Issue
- 3
- Pages
- 150-157
- ISSN
- 1743-4254 (ISSN-L)
- 1743-4262
- OpenAlex
- W2052453190
- Cited by
- 330
- References
- 46
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.